Esperion Therapeutics’ (ESPR) Buy Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC restated their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR) in a research note published on Friday morning,Benzinga reports. The firm currently has a $6.00 price objective on the biopharmaceutical company’s stock.

ESPR has been the subject of a number of other reports. StockNews.com downgraded Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 15th. HC Wainwright restated a “buy” rating and set a $16.00 price target on shares of Esperion Therapeutics in a research note on Thursday.

Esperion Therapeutics Stock Performance

Esperion Therapeutics stock opened at $2.25 on Friday. The company has a market cap of $443.34 million, a price-to-earnings ratio of -3.52 and a beta of 1.01. Esperion Therapeutics has a 1 year low of $1.58 and a 1 year high of $3.94. The firm has a 50 day moving average price of $2.39 and a 200 day moving average price of $2.22.

Hedge Funds Weigh In On Esperion Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in ESPR. BOKF NA purchased a new position in Esperion Therapeutics in the second quarter valued at about $26,000. Xponance Inc. purchased a new stake in shares of Esperion Therapeutics during the 2nd quarter valued at about $28,000. Traphagen Investment Advisors LLC purchased a new stake in shares of Esperion Therapeutics during the 3rd quarter valued at about $27,000. National Bank of Canada FI boosted its holdings in Esperion Therapeutics by 115.9% in the 2nd quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company’s stock worth $44,000 after acquiring an additional 10,225 shares during the period. Finally, Sivia Capital Partners LLC purchased a new position in Esperion Therapeutics in the 2nd quarter worth approximately $44,000. Institutional investors and hedge funds own 47.39% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.